Evidence map›Paper›PMID 40134683›Full record

ArticleRSC advances2025

PD-L1 blockade peptide-functionalized NaGdF

Zhenzhen Hu, Yunkai Bao, Xiaodong Li, Zhuheng Li, Peihong Teng, Guifeng Liu, Zhenxin Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhenzhen HuDepartment of Radiology, China-Japan Union Hospital of Jilin University Changchun 130033 P. R. China gfliu@jlu.edu.cn.
Yunkai BaoState Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences Changchun 130022 P. R. China wangzx@ciac.ac.cn.
Xiaodong LiDepartment of Radiology, China-Japan Union Hospital of Jilin University Changchun 130033 P. R. China gfliu@jlu.edu.cn.
Zhuheng LiJilin Provincial Institute of Education Changchun 130024 P. R. China lizhuheng@126.com.
Peihong TengDepartment of Radiology, China-Japan Union Hospital of Jilin University Changchun 130033 P. R. China gfliu@jlu.edu.cn.
Guifeng LiuDepartment of Radiology, China-Japan Union Hospital of Jilin University Changchun 130033 P. R. China gfliu@jlu.edu.cn.
Zhenxin WangState Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences Changchun 130022 P. R. China wangzx@ciac.ac.cn.ORCID https://orcid.org/0000-0002-1908-9848

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint blockade (ICB) inhibitors have shown great promise for the treatment of numerous types of cancers, including triple-negative breast cancer (TNBC), by interrupting immunosuppressive checkpoints. Herein, programmed cell death ligand 1 (PD-L1) blockade peptide-functionalized NaGdF

Identifiers

PMID40134683
PMCPMC11934231

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.